(Health Korea News / Chang-yong Lee) It is predicted that the global tissue diagnosis market will reach $10.92 billion (KRW 15.2912 trillion) by 2029. Tissue diagnosis is a medical procedure in which a doctor diagnoses a disease by analyzing tissue samples obtained from a patient.
Lee Yoo-rim, a researcher at the National Biotechnology Policy Research Center, said in a report titled ‘Global Growth Opportunities for the Tissue Diagnostics Industry’ that included this content, the market size, which was $6.79 billion (KRW 9.4924 trillion) as of 2023, has increased by 8.7% each year. It is expected to grow steadily, reaching $10.92 billion (KRW 15.2661 trillion) in 2029.
The global cancer incidence rate is expected to increase by 60% by 2040, and the resulting demand for tissue diagnosis and advanced diagnostic tools is expected to increase the size of the tissue diagnosis market.
The government and state medical institutions are also investing more budget in screening programs for major cancers such as breast cancer, lung cancer, cervical cancer, and colon cancer, which is expected to lead to the growth of the tissue diagnosis market.
The tissue diagnostics industry is divided into advanced staining, pre-analysis, and ICP-APLIS (Integrated Computer Pathology and Anatomic Pathology Laboratory Information System), which enable accurate biomarker identification. Among these, profits from advanced dyeing technology account for the largest proportion.
As of 2023, the luxury dyeing market size accounted for the largest share at $4.08 billion, followed by preliminary analysis and ICP-APLIS at $2.13 billion and $570 million, respectively. This share of market share is expected to continue until 2029.
In the case of the advanced dyeing market, it is analyzed that awareness of the need for early diagnosis, increasing demand for accurate cancer diagnosis, and advancements in targeted treatment and personalized medicine are leading.
In fact, academic institutions continue to cooperate with tissue diagnosis companies to lead technological advancements and support sales growth.
Roche’s BenchMark ULTRA system is considered an example of innovation in the advanced dyeing field. This is because it has full automation and high throughput, which can improve diagnostic efficiency.
Preliminary analysis suggests that demand for automated dyeing platforms will lead growth. Traditional samples are manually embedded in frozen sections (a process of solidifying tissue pieces in a hard medium such as paraffin), which is not only labor-intensive but can also cause tissue distortion and tissue inconsistency, reducing diagnostic reliability. am.
Automation platforms can help address accuracy issues as well as cost by automating sample preparation, streamlining next-generation sequencing (NGS) steps and reducing manual steps.
In fact, it was found that implementing automation systems in hospitals, diagnostic centers, laboratories, etc. can reduce direct work hours by 14.1% and save about 1,432 hours of labor each year.
The growth of ICP-APLIS is likely to be driven by the need for advanced diagnostic tools and the rapid adoption of digitalization following the COVID-19 pandemic.
ICP-APLIS can revolutionize anatomic pathology by integrating traditional laboratory data with digital pathology analysis.
ICP-APLIS uses machine learning algorithms to analyze large amounts of data, detect patterns, and improve diagnostic accuracy. It enables precise diagnosis by studying high-resolution digital slides and the patient’s entire medical history data.
Looking at the revenue ranking by region, as of 2023, North America is $2.27 billion (KRW 3.1759 trillion), Europe is $1.77 billion (KRW 2.4764 trillion), and Asia Pacific is $1.67 billion (KRW 2.3364 trillion). ), Menasa (Middle East and North Africa) and Latin America 630 million. It was followed by dollars (881.3 billion won). This revenue ranking will be maintained until 2026, but the Asia Pacific region is expected to surpass Europe from 2027.
Looking at the projected revenue by region in 2027, North America is expected to rank first with $3.56 billion (KRW 4.9804 trillion), followed by Asia Pacific with $2.44 billion (KRW 3.4128 trillion). Europe is expected to fall one level to third place with $2.36 billion (3.3 trillion won).
Meanwhile, there are several factors that may limit the growth of the tissue diagnostics market. The U.S. Medicare Protection Act is one of them. As a result of the implementation of the Medicare Protections Act, reimbursement for pathology services has decreased, which may impact provider revenue generation.
The complex approval process for new tissue diagnosis technologies is also considered another factor. This is because it can delay the market entry of new tissue diagnostic technologies and limit the use of new technologies in laboratories.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
